Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Efavirenz on Suzetrigine PK in Healthy Subjects
NCT07570069Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of suzetrigine in pain, sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at Day 30 and Area Under the Concentration Versus Time Curve During a Dosing Interval at Day 30. Started May 2026; status: completed.
02
Drugs
suzetrigine
03
Conditions
pain
Beyond the preview
Go deeper on NCT07570069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570069.